We are live on ! Find out more
ADMA icon

ADMA Biologics
ADMA

27 hedge funds and large institutions have $55.1M invested in ADMA Biologics in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

225% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 4

17% more funds holding

Funds holding: 23 → 27 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

19% less capital invested

Capital invested by funds: $68.1M → $55.1M (-$13.1M)

Holders
27
Holders Change
+4
Holders Change %
+17.39%
% of All Funds
0.72%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
5
Increased
13
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$1.5M
2
BC
Broadfin Capital
New York
+$1.04M
3
IHM
Iguana Healthcare Management
New York
+$875K
4
SM
Sabby Management
Florida
+$700K
5
PVI
Pura Vida Investments
New York
+$256K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$28.4K
2
UBS Group
UBS Group
Switzerland
-$21.2K
3
WMSA
Weiss Multi-Strategy Advisers
New York
-$19.9K
4
Morgan Stanley
Morgan Stanley
New York
-$2.02K

ADMA Hedge Fund Activity: Q2 2016 in Review

27 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q2 2016, worth a combined $55.1M — down 19% from $68.1M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ADMA positions and 1 closed out — a net gain of 4 holders — while 13 added to existing stakes and 4 trimmed.

The largest buyer was Consonance Capital Management, adding an estimated $1.5M. The largest seller was Tower Research Capital (TRC), cutting an estimated $28.4K.

  • 27 institutional investors held ADMA Biologics (ADMA) as of Q2 2016, up from 23 in Q1 2016.
  • Funds reported $55.1M of ADMA Biologics stock for Q2 2016, down 19% quarter-over-quarter.
  • 5 funds opened new ADMA Biologics positions in Q2 2016 and 1 closed out, a net change of +4 holders.
  • The largest ADMA Biologics buyer in Q2 2016 was Consonance Capital Management, an estimated $1.5M added.
  • The largest ADMA Biologics seller in Q2 2016 was Tower Research Capital (TRC), an estimated $28.4K sold.

Based on aggregated 13F filings for Q2 2016.